Gaetano Corazzelli

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

PET2-Adapted Therapy in Patients With Advanced-Stage Hodgkin Lymphoma Treated With Frontline ABVD: Searching for the Baby in the Bathwater.

PET2-Adapted Therapy in Patients With Advanced-Stage Hodgkin Lymphoma Treated With Frontline ABVD: Searching for the Baby in the Bathwater.

Journal: Hematological oncology

Published: October 08, 2024

Long-term efficacy and safety of dose-dense and dose-intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15-year follow-up of the ABVDDD-DI phase II study.

Long-term efficacy and safety of dose-dense and dose-intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15-year follow-up of the ABVDDD-DI phase II study.

Journal: British journal of haematology

Published: May 28, 2024

Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers.

Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers.

Journal: Cancers

Published: January 17, 2021

Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma.

Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma.

Journal: British journal of haematology

Published: August 06, 2018

Dendritic cells in hematological malignancies.

Dendritic cells in hematological malignancies.

Journal: Critical reviews in oncology/hematology

Published: April 28, 2016

Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma: reply to D'Arco et al.

Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma: reply to D'Arco et al.

Journal: British journal of haematology

Published: April 21, 2015

MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.

MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years.

Journal: Neurology

Published: March 18, 2014

A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.

A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.

Journal: British journal of haematology

Published: January 02, 2014

BCL10 expression and localization in ocular adnexa MALT lymphomas: a comparative cytogenetic and immunohistochemical study.

BCL10 expression and localization in ocular adnexa MALT lymphomas: a comparative cytogenetic and immunohistochemical study.

Journal: Histology and histopathology

Published: July 13, 2013

Pediatric Hodgkin Lymphoma: on the road to a 'radiotherapy-free' cure rate?-Commentary on a report on final results of the Multinational Trial GPOH-HD95.

Pediatric Hodgkin Lymphoma: on the road to a 'radiotherapy-free' cure rate?-Commentary on a report on final results of the Multinational Trial GPOH-HD95.

Journal: Translational pediatrics

Published: July 01, 2013

Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.

Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.

Journal: British journal of haematology

Published: July 16, 2012

RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.

RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.

Journal: British journal of haematology

Published: November 22, 2011

Showing 1-12 of 14

Last Updated: 09/26/2026